ECM
ACOR

Everence Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Everence Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-547
Closed -$61K – 676
2020
Q1 		$61K Hold
547
– – 0.01% 603
2019
Q4 		$134K Buy
+547
New +$138K 0.02% 649

Other funds holding ACOR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Everence Capital Management's ACOR Position: Q2 2020 in Review

Everence Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 547 shares — an estimated $61K sold.

Everence Capital Management first reported a position in ACOR in Q4 2019 and held it in 2 quarters. The position peaked at $134K in Q4 2019. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

  • Everence Capital Management reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Everence Capital Management sold 547 Acorda Therapeutics shares in Q2 2020, an estimated $61K.
  • Everence Capital Management first reported a position in Acorda Therapeutics in Q4 2019 and held it in 2 quarters.
  • Everence Capital Management's Acorda Therapeutics position peaked at $134K in Q4 2019.
  • 79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on Everence Capital Management's 13F filing for Q2 2020, filed 7 Jul 2020.